AstraZeneca: three new approvals ahead in EU

(CercleFinance.com) - AstraZeneca announced on Monday that three of its blockbuster cancer drugs have been recommended for new indications in Europe by the Committee for Medicinal Products for Human Use (CHMP).


Enhertu, the antibody-drug conjugate (ADC) that the company is developing with Japan's Daiichi Sankyo, has received a positive opinion from the European Medicines Agency (EMA) for the treatment of advanced HER2-positive stomach cancer.

Meanwhile, Imfinzi has been recommended by the CHMP for marketing in the EU as a first-line treatment for non-operable or metastatic biliary tract cancer, in addition to chemotherapy.

The CHMP also adopted a positive opinion for the marketing of Lynparza for the treatment of metastatic castration-resistant prostate cancer in patients who are not eligible for chemotherapy.


Copyright (c) 2022 CercleFinance.com. All rights reserved.